RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy���An age-group analysis.

Citation

• Muro, K., Bodoky, G., Cesas, A., Chao, Y., Clingan, P., Hironaka, S., . . . Wilke, H. (2015). RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy���An age-group analysis.. Journal of Clinical Oncology, 33(3_suppl), 11. doi:10.1200/jco.2015.33.3_suppl.11

Digital Object Identifier (doi)

• 10.1200/jco.2015.33.3_suppl.11

Web Of Science Accession Number

Start Page

• 11

End Page

• 11

Volume

• 33

Issue

• 3_suppl

Place Of Publication

Abstract

UOW Authors

•   Clingan, Phillip (external author)

Publication Date

• 2015

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Muro, K., Bodoky, G., Cesas, A., Chao, Y., Clingan, P., Hironaka, S., . . . Wilke, H. (2015). RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy���An age-group analysis.. Journal of Clinical Oncology, 33(3_suppl), 11. doi:10.1200/jco.2015.33.3_suppl.11

Digital Object Identifier (doi)

• 10.1200/jco.2015.33.3_suppl.11

Web Of Science Accession Number

Start Page

• 11

End Page

• 11

Volume

• 33

Issue

• 3_suppl

Place Of Publication